Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

On September 7, 2022, Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Russ Trenary will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The biopharmaceutical company is focused on launching the first FDA-approved ophthalmic formulation of bevacizumab, known as ONS-5010, for retinal conditions like wet AMD. Investors can attend one-on-one meetings, and a webcast of the presentation will be available on-demand from September 12. For more details, visit the company's website.

ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Anna Army
Account Supervisor
LaVoie Health Science
T: 617-351-0246
aarmy@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

When will Outlook Therapeutics present at the H.C. Wainwright Conference?

Outlook Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

What is ONS-5010 and its significance?

ONS-5010, also known as bevacizumab-vikg, aims to be the first FDA-approved ophthalmic formulation for treating retinal diseases.

How can investors engage with Outlook Therapeutics at the conference?

Investors registered for the conference can participate in virtual one-on-one meetings with Outlook Therapeutics' management.

Is there a webcast available for the Outlook Therapeutics presentation?

Yes, a video webcast of the presentation will be available on-demand from September 12, 2022.

What diseases does ONS-5010 target?

ONS-5010 targets retinal conditions, including wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).